Moreover, another study demonstrated an average CDKN2B hypomethylation of 6.8% in 47% of the patients with azacitidine, [87] which corroborated with the suppression of CDKN2B and tumor growth in SKM-1 cell lines in vitro [88]. This evidence concerns the gene CDKN2B and neoplasm.